Posted in | News | Gold | Copper | Mining Business

EMED Mining Raises $2.4 Million

EMED Mining's recent IPO in Canada was oversubscribed and has raised Canadian $2.4 million. The company is focused on exploring and developing resources of copper and gold.

The company completed the IPO in Toronto just before Christmas and a concurrent private placement in London.

The mining company has placed about 180,970,000 in Canada with a value of about 8.5 pence or Canadian $0.135. It had also granted it agents in Canada an over-allotment option of 18,145,500 shares all of which were used. The syndicate of agents led by Canaccord Genuity Corporation included GMP Securities L.P. and Paradigm Capital Inc.

They have raised Canadian $24.43 million overall. The company has interests in Europe and the Middle East. This included past mining centers with under explored potential for different types of mineralization. The company primarily focuses on volcanogenic-hosted massive sulphide copper-gold, epithermal gold and porphyry copper-gold. The main asset for EMED Mining is the Rio Tinto copper mine redevelopment project in the Andalucia region of Spain.

EMED Mining is listed on the AIM market (Code: EMED) of the London Stock Exchange and on the Toronto Stock Exchange (Code: EMD).
 

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chai, Cameron. (2019, February 18). EMED Mining Raises $2.4 Million. AZoMining. Retrieved on May 05, 2024 from https://www.azomining.com/News.aspx?newsID=2490.

  • MLA

    Chai, Cameron. "EMED Mining Raises $2.4 Million". AZoMining. 05 May 2024. <https://www.azomining.com/News.aspx?newsID=2490>.

  • Chicago

    Chai, Cameron. "EMED Mining Raises $2.4 Million". AZoMining. https://www.azomining.com/News.aspx?newsID=2490. (accessed May 05, 2024).

  • Harvard

    Chai, Cameron. 2019. EMED Mining Raises $2.4 Million. AZoMining, viewed 05 May 2024, https://www.azomining.com/News.aspx?newsID=2490.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.